Summary
There is now considerable evidence that nitric oxide (NO) production and action are abnormal in patients with heart failure. Spontaneous NO release from the vascular endothelium is preserved or enhanced in patients with heart failure and this may help to maintain tissue perfusion by blunting the vasoconstriction induced by various neurohumoral factors. On the other hand, endothelial NO release in response to various stimuli including exercise appears to be diminished and this may contribute to the impaired exercise capacity of patients with heart failure.
It is now apparent that NO produced within the heart plays an important role in the modulation of cardiac contractility under physiological conditions. In patients with heart failure, however, increased myocardial NO production in response to cytokines such as tumour necrosis factor-α may contribute to reduced contractility and myocyte injury.
Our understanding of the role of NO in the control of vascular tone has provided an explanation for the efficacy of nitrovasodilators in heart failure and has stimulated novel approaches to augmenting endogenous vascular NO production. There is also evidence that ACE inhibitors act to restore normal endothelial function in patients with heart failure.
Increased NO production within the heart, particularly that produced via the pro-inflammatory inducible NO synthase, may be detrimental. It remains to be determined whether selective inhibition of inducible NO synthase can favourably modify the course of this lethal condition.
Similar content being viewed by others
References
Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43(2): 109–42
Bassenge E. Coronary vasomotor responses: role of endothelium and nitrovasodilators. Cardiovasc Drugs Ther 1994; 8(4): 601–10
Kaiser L, Spickard RC, Olivier NB. Heart failure depresses endothelium-dependent responses in canine femoral artery. Am J Physiol 1989; 256 (4 Pt 2): H962–7
Drexler H, Lu W. Endothelial dysfunction of hindquarter resistance vessels in experimental heart failure. Am J Physiol 1992; 262 (6 Pt 2): H1640–5
Treasure CB, Vita JA, Cox DA, et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 1990; 81: 772–9
Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84: 1589–96
O’Murchu B, Miller VM, Perella MA, et al. Increased production of nitric oxide in coronary arteries during congestive heart failure. J Clin Invest 1994; 93: 165–71
Hirooka Y, Imaizumi T, Harada S, et al. Endothelium-dependent forearm vasodilation to acetylcholine but not to substance P is impaired in patients with heart failure. J Cardiovasc Pharmacol 1992; 20 Suppl. 12: S221–5
Drexler H, Hayoz D, Munzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69(19): 1596–601
Kubo SH, Rector TS, Bank A, et al. Lack of contribution of nitric oxide to basal vasomotor tone in heart failure. Am J Cardiol 1994; 74: 1133–6
Habib F, Dutka D, Crossman D, et al. Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism? Lancet 1994; 344: 371–3
Winlaw DS, Smythe GA, Keogh AM, et al. Increased nitric oxide production in heart failure. Lancet 1994; 344: 373–4
Winlaw D, Smythe G, Keogh A, et al. Nitric oxide production and heart failure. Lancet 1995; 345: 390–1
Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236–41
McMurray J, Abdullah I, Dargie HJ, et al. Increased concentrations of tumour necrosis factor in ‘cachectic’ patients with severe chronic heart failure. Br Heart J 1991; 66(5): 356–8
Katz SD, Rao R, Berman JW, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive cardiac failure: relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994; 90(1): 12–6
Wiedermann C, Beimpold H, Herold M, et al. Increased levels of serum neopterin and decreased production of neutropil superoxide anions in chronic heart failure with elevated levels of tumour necrosis factor-alpha. J Am Coll Cardiol 1993; 22(7): 1897–1901
Yoshizumi M, Perrella MA, Burnett JC, et al. Tumor necrosis factor downregulates an endothelial nitric oxide synthase messenger RNA by shortening its half-Life. Circ Res 1993; 73(1): 205–9
Matsubara T, Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines. J Immunol 1986; 137(10): 3295–8
Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990; 275(1–2): 87–90
Gross SS, Jaffe EA, Levi R, et al. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochem Biophys Res Commun 1991; 178(3): 823–9
Hirooka Y, Imaizumi T, Tagawa T, et al. Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with heart failure. Circulation 1994; 90: 658–68
Balligand JL, Kelly RA, Marsden PA, et al. Control of cardiac muscle cell function by an endogenous nitric oxide signalling system. Proc Natl Acad Sci USA 1993; 90: 347–51
Shah AM, Smith JA, Lewis MJ. The role of the endocardium in the modulation of contraction of isolated papillary muscles of the ferret. J Cardiovasc Pharmacol 1991; 17 Suppl. 3: S251–7
Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257(5068): 387–9
Balligand JL, Ungureanu D, Kelly RA, et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993; 91(5): 2314–9
Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Circulation 1994; 89: 2070–8
De Belder AJ, Radomski MW, Why HJF, et al. Nitric oxide synthase activities in human myocardium. Lancet 1993; 341: 84–5
Hatler B, Oddis C, Zeevi A, et al. Regulation of constitutive nitric oxide synthase activity by the human heart. Am J Cardiol 1995; 76: 957–9
Studer R, Käster S, Reinecke H, et al. Myocardial gene expression of endothelial NO synthase in ischaemic and dilative cardiomyopathy [abstract]. Eur Heart J 1994; 15 Suppl. 1: P265
Studer R, Käster S, Just H, et al. Myocardial gene expression of nitric oxide synthase in ischaemic and dilated cardiomyopathy. Circulation 1994; 90 (4 Pt 2): I–547, abstract 2946
Haywood G, Tsao P, Leyen HVD, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996; 93(6): 1087–94
Moncada S. The L-arginine-nitric oxide pathway. Acta Physiol Scand 1992; 145: 201–7
Pinsky DJ, Cai B, Yang X, et al. Nitric oxide-dependent killing of cardiac myocytes by adjacent macrophages. Circulation 1994; 90 (4 Pt 2): I–192, abstract 1028
Pinsky DJ, Cai B, Yang X, et al. Cytokine-inducible NO-dependent autotoxicity of cardiac myocytes. Circulation 1994; 90 (4 Pt 2): I–192 abstract 1030
Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray? J Am Coll Cardiol 1993; 22 (4 Suppl. A): 119A–26A
Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) trial study group. Lancet 1993: 342(8885): 1441–6
Vegh A, Szekeres L, Parratt J. Preconditioning of the ischaemic myocardium: involvement of the L-arginine nitric oxide pathway. Br J Pharmacol 1992; 107: 648–52
Schoelkens BA, Linz W. Bradykinin-mediated metabolic effects in isolated perfused rat hearts. Agents Actions 1992; 38 Suppl. II: 36–42
Fung HL. Clinical pharmacology of organic nitrates. Am J Cardiol 1993; 72: 9C–13C
Murrell W. Nitroglycerin as a remedy for angina pectoris. Lancet 1879; I: 80–1
Fung HL, Kowalak EA, Chung SJ, et al. Nitric oxide generation from nitrovasodilators in coronary artery smooth muscle cells is mediated by multiple enzymes. In: Moncada MMS, Hibbs Jr JB, Higgs EA, editors. Biology of nitric oxide: Part 1. Physiology and clinical aspects. Colchester: Portland Press, 1992: 139–41
Guiha NH, Cohn JN, Mikulic E, et al. Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med 1974; 291: 587–92
Leier CV, Bambach D, Thompson MJ, et al. Central and regional hemodynamic effects of intravenous isosorbide dinitrate, nitroglycerin and nitroprusside in patients with congestive heart failure. Am J Cardiol 1981; 48: 1115–23
Franciosa JA, Blank RC, Cohn JN. Nitrate effects on cardiac output and left ventricular outflow resistance in chronic congestive heart failure. Am J Med 1978; 64: 207–13
Ribner HS, Bresnahan D, Hsieh AM, et al. Acute hemodynamic responses to vasodilator therapy in congestive heart failure. Prog Cardiovasc Dis 1982; 25: 1–42
Nelson GIC, Silke B, Ahuya RC, et al. Haemodynamic advantages of isosorbide dinitrate over frusemide in acute heart failure following myocardial infarction. Lancet 1983; I: 730–3
Cohn JN, Archibald DG, Zeische S, et al. Effects of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration cooperative study (VHeFT). N Engl J Med 1986; 314: 1547–52
Cohn JN, Johnson G, Zeische S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10
Elkayam U, Mehra A, Shotan A, et al. Nitrate resistance and tolerance: potential limitations in the treatment of congestive heart failure. Am J Cardiol 1992; 70: 98B–104B
Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther 1994; 8: 489–99
Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987; 317: 799–804
Sharpe N, Coxon R, Wester M, et al. Hemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure. Am J Cardiol 1987. 59: 895–9
Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerin-induced tolerance in experimental heart failure. Circulation 1991; 84: 35–9
Unger P, Berkenboom G, Fontaine J. Interaction between hydralazine and nitrovasodilators in vascular smooth muscle. J Cardiovasc Pharmacol 1993; 21: 478–83
Dakak N, Makhoul N, Flugelman MY, et al. Failure of Captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990; 66: 608–13
Katz RJ, Levy WS, Buff L, et al. Prevention of nitrate tolerance with angiotensin-converting enzyme inhibitors. Circulation 1991. 83: 1271–7
Mehra A, Ostrzega E, Shotan A, et al. Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with Captopril. Am J Cardiol 1992; 70: 1310–4
Han YL, Tong M, Jing QM. A study of Captopril enhancement of nitrate effect in coronary arterial disease patients associated with heart failure. Chin J Intern Med 1994; 33: 455–8
Mombouli J, Illiano S, Nagao T, et al. The potentiation of endothelium-dependent relaxations to bradykinin by angiotensin converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and contracting factors. Circ Res 1992; 71: 137–44
Mulder P, Devaux B, Fertak LE, et al. Vascular and myocardial protective effects of converting enzyme inhibition in experimental heart failure. Am J Cardiol 1995; 76 Suppl.: 28E–33E
Drexler H, Kurz S, Jeserich M, et al. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am J Cardiol 1995; 76 Suppl.: 13E–8E
Koifman B, Wollman Y, Bogomolny N, et al. Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. J Am Coll Cardiol 1995; 26: 1251–6
Kubo S, Rector T, Bank A, et al. Chronic oral L- arginine improves forearm blood flow during exercise and reactive hyperemia in patients with heart failure. Circulation 1994; 90(4): I–602
Morley D, Maragos CM, Zhang XY, et al. Mechanism of vascular relaxation induced by the nitric oxide (NO)/nucleophile complexes, a new class of NO-based vasodilators. J Cardiovasc Pharmacol 1993; 21(4): 670–6
Shaffer JE, Lee F, Thomson S, et al. The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs. J Pharmacol Exp Ther 1991; 256(2): 704–9
Rossaint R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328(6): 399–405
Macdonald P, Mundy J, Rogers P, et al. Successful treatment of life-threatening acute reperfusion injury after lung transplantation with inhaled nitric oxide. J Thorac Cardiovasc Surg 1995; 110: 861–3
Kieler-Jensen N, Rickstein S-E, Stenqvist S-E, et al. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 1994; 13: 366–75
Loh E, Stamler J, Hare J, et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994; 90: 2780–5
Semigran M, Cockrill B, Kacmarek R, et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994; 24: 982–8
Hayward C, Rogers P, Keogh A, et al. Inhaled nitric oxide in cardiac failure: vascular versus ventricular effects. J Cardiovasc Pharmacol. In press
Bocchi E, Bacal F, Auler JJ. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol 1994; 74: 70–3
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Macdonald, P., Schyvens, C. & Winlaw, D. The Role of Nitric Oxide in Heart Failure. Drugs & Aging 8, 452–458 (1996). https://doi.org/10.2165/00002512-199608060-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-199608060-00007